natgillin/translations-raw huggingface dataset:
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Pojavnost laktacidoze je mogoče in tudi potrebno zmanjševati z oceno drugih povezanih dejavnikov tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajno stradanje, čezmerno uživanje alkohola, jetrna insuficienca in katera koli stanja, povezana s hipoksijo.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors, such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia (see also sections 4.3 and 4.5).
Pogostnost laktacidoze je mogoče in tudi potrebno zmanjšati s presojo drugih sočasnih dejavnikov tveganja, kot so slabo urejen diabetes, ketoza, dolgotrajno stradanje, prekomerno uživanje alkohola, jetrna insuficienca in katerakoli s hipoksijo povezana bolezen (glejte tudi poglavji 4.3 in 4.5).
The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.
Incidenco laktacidoze je možno in tudi potrebno zmanjševati z oceno drugih povezanih dejavnikov tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajno stradanje, čezmerno uživanje alkohola, jetrna insuficienca in katerakoli stanja, povezana s hipoksijo.
The incidence of late ALT elevations was not affected by treatment duration.
Trajanje zdravljenja ni vplivalo na pojavnost zakasnelih zvišanj ALT.
The incidence of lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population.
V kliničnih študijah je bila pogostnost primerov limfoma (B-celičnega in T-celičnega) večja od njihove pričakovane pogostnosti v splošni populaciji.
The incidence of malignancies reported in ustekinumab-treated patients was comparable to the incidence expected in the general population (standardised incidence ratio = 0.87 [95% confidence interval: 0.66, 1.14], adjusted for age, gender and race).
Pogostnost malignomov, poročanih pri bolnikih, zdravljenih z ustekinumabom, je bila podobna pričakovani pogostnosti v splošni populaciji (standardiziran količnik incidence = 0,92 [95% interval zaupanja: 0,69, 1,20], prilagojen za starost, spol in raso).
The incidence of malignancy in MabThera treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical study was 2.00 per 100 patient years at the study common closing date (when the final patient had completed the follow-up period).
Incidenca malignih bolezni med bolniki, ki so v klinični študiji pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom prejemali zdravilo MabThera, je bila ob končnem zaključnem datumu študije (tj. ko je zadnji bolnik dokončal obdobje spremljanja) 2,00 na 100 bolnik- let.
The incidence of malignancy in MabThera treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical trial was 2.00 per 100 patient years at the trial common closing date (when the final patient had completed the follow-up period).
Incidenca malignih bolezni med bolniki, ki so v klinični študiji pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom prejemali zdravilo MabThera, je bila ob končnem zaključnem datumu študije (tj. ko je zadnji bolnik dokončal obdobje spremljanja) 2,00 na 100 bolnik- let.
The incidence of nausea was 24.5% in the lixisenatide group compared to 35.1% in the exenatide twice daily group and the incidence of symptomatic hypoglycaemia with lixisenatide was 2.5% during the 24-week main treatment period compared to 7.9% in the exenatide group.
Incidenca navzee je bila v skupini, ki je prejemala zdravilo Lyxumia 24,5 % in v skupini, ki je prejemala eksenatid dvakrat na dan 35,1 %, incidenca simptomatskih hipoglikemij pa je bila med 24- tedenskim glavnim obdobjem zdravljenja z zdravilom Lyxumia 2,5 % in z eksenatidom 7,9 %.
The incidence of nausea was 24.5% in the lixisenatide group compared to 35.1% in the exenatide twice daily group and the incidence of symptomatic hypoglycaemia with lixisenatide was 2.5% during the 24-week main treatment period compared to 7.9% in the exenatide group.
Incidenca navzee je bila v skupini, ki je prejemala zdravilo Lyxumia 24,5 % in z eksenatidom dvakrat na dan 35,1 %, incidenca simptomatskih hipoglikemij pa je bila med 24-tedenskim glavnim obdobjem zdravljenja z zdravilom Lyxumia 2,5 % in z eksenatidom 7,9 %.
The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated patients vs 5.1% in placebo-treated patients.
Incidenca diareje 3. in 4. stopnje po merilih NCI-CTCAE je bila v skupini, ki je prejemala zdravilo Perjeta, 9,3-% in v skupini, ki je prejemala placebo, 5,1-%.
The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births.
Pojavnost okvar nevralne cevi pri prebivalstvu na splošno se giblje med 0,5–1 primer na 1000 živorojenih otrok.
The incidence of neutropenia grade 3 or 4 reported as adverse reactions was higher in multiple myeloma patients receiving MPT (Melphalan, Prednisone, Thalidomide) than in those receiving MP (Melphalan, Prednisone): 42.7% versus 29.5% respectively (study IFM 99-06).
Incidenca nevtropenije 3. ali 4. stopnje v okviru poročanj neželenih učinkov je bila višja pri bolnikih z diseminiranim plazmocitomom, ki so prejemali MPT (melfalan, prednizon, talidomid), kot pri tistih, ki so prejemali MP (melfalan, prednizon): 42,7 % v primerjavi z 29,5 % (študija IFM 99-06).
The incidence of neutropenia was higher in the Gazyvaro plus bendamustine (G+B) arm compared to the bendamustine (B) alone arm (38% and 32%, respectively).
Incidenca nevtropenije je bila s kombinacijo zdravila Gazyvaro in bendamustina (G + B) večja (38 %) kot pri samostojni uporabi bendamustina (B) (32 %).
The incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with Enbrel than in the control group.
Incidenca nekožnih malignih obolenj različnih tipov je bila pomembno večja pri bolnikih, zdravljenih z zdravilom Enbrel, kot pri tistih v kontrolni skupini.
The incidence of non-melanoma skin cancer was 0.48 per 100 patient-years of follow-up for ustekinumab-treated patients (4 patients in 829 patient-years of follow-up) compared to 0.52 for placebo-treated patients (2 patients in 385 patient-years of follow-up).
Incidenca nemelanomskega kožnega raka je znašala 0,65 na 100 bolnikov-let spremljanja za bolnike, zdravljene z ustekinumabom (4 bolniki na 615 bolnikov-let spremljanja), v primerjavi z 0,70 za bolnike, ki so prejemali placebo (2 bolnika na 287 bolnikov-let spremljanja).
The incidence of oral/skin lesions increases with increasing dose.
Poškodbe kože in sluznice so z zvišanjem odmerkov pogostejše.
The incidence of orthostatic hypotension in placebo-controlled clinical studies was 1.2 % with silodosin and 1.0 % with placebo.
V s placebom nadzorovanih kliničnih študijah je bila pogostnost ortostatske hipotenzije ob uporabi silodozina 1,2% in ob uporabi placeba 1,0%.
The incidence of pancreatitis (adjudicated as likely to be related to therapy) in the clinical studies was 0.3% for Eperzan compared to 0% for placebo and 0.1% for comparators (i.e. liraglutide, pioglitazone, glimepiride, sitagliptin, and insulin glargine) with or without additional background antidiabetic therapy (e.g. metformin).
Incidenca pankreatitisa (po presoji ocenjenega kot verjetno povezanega z zdravljenjem) je bila v kliničnih študijah 0,3 % za zdravilo Eperzan, 0 % za placebo in 0,1 % za primerjalna zdravila (tj. liraglutid, pioglitazon, glimepirid, sitagliptin in insulin glargin), z dodatno osnovno antidiabetično terapijo (npr. metformin) ali brez nje.
The incidence of patients with triglyceride elevations > 5 x upper limit of normal (ULN) was 2.4% with Ilaris and 0.7% with triamcinolone acetonide.
Pri bolnikih z zdravilom Ilaris je bila pogostnost zvišanja na več kot 5-kratnik zgornje meje normalnih vrednosti 2,4 %, pri bolnikih s triamcinolon acetonidom pa 0,7 %.
The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs.
Incidenca perifernih edemov je bila nižja v skupini z vildagliptinom v primerjavi s skupino z rosiglitazonom (2,1 % v primerjavi s 4,1 %).
The incidence of post-dose symptoms occuring within the first three days after administration of zoledronic acid can be reduced with the administration of paracetamol or ibuprofen shortly following zoledronic acid administration.
Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zdravila Zoledronska kislina Teva Generics, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zdravila Zoledronska kislina Teva Generics.
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Pharma can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Pharma administration
Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zdravila Zoledronska kislina Teva Pharma, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zdravila Zoledronska kislina Teva Pharma.
The incidence of post-dose symptoms occurring within the first three days after administration of Zoledronic Acid Hospira can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic Acid Hospira administration.
Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zoledronske kisline, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zoledronske kisline.
The incidence of potentially clinically significant decreases in lymphocyte counts (<0.5 x 109/L) (<1%), neutrophil counts (≤1.0 x 109/L) (<1%) and platelet counts (≤100 x 109/L) (≤1%) was similar in Plegridy-treated patients compared to placebo-treated patients.
Incidenca potencialno klinično pomembnega zmanjšanja števila limfocitov (< 0,5 x 109/l) (< 1 %), števila nevtrofilcev (≤ 1,0 x 109/l) (< 1 %) in števila trombocitov (≤ 100 x 109/l) (≤ 1 %) je bila pri bolnikih, zdravljenih z zdravilom Plegridy, podobna kot pri bolnikih, ki so prejemali placebo.
The incidence of pre- existing antibodies to romiplostim and TPO was 8.0% and 5.4%, respectively.
Incidenca že obstoječih protiteles proti romiplostimu je bila 8,0% in proti TPO 5,4%.
The incidence of rash was higher in patients who received six cycles of Perjeta compared with patients who received three cycles of Perjeta, independent of the chemotherapy given.
Incidenca izpuščaja je bila večja pri bolnikih, ki so prejeli 6 ciklov zdravila Perjeta, v primerjavi z bolniki, ki so prejeli tri cikle zdravila Perjeta, neodvisno od prejete kemoterapije.
The incidence of rash was higher in women compared to men in the INTELENCE arm in the DUET trials (rash ≥ grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) (see section 4.4).
Incidenca tega izpuščaja je bila večja pri ženskah kot pri moških iz kraka preskušanja DUET z zdravilom INTELENCE (izpuščaj ≥ 2. stopnje so poročali pri 9/60 [15,0%] žensk v primerjavi z 51/539 [9,5%] moških; o prekinitvi zdravljenja zaradi izpuščaja so poročali pri 3/60 [5,0%] ženskah v primerjavi z 10/539 [1,9%] moških) (glejte poglavje 4.4).
The incidence of relapse during the 6- months double-blind follow-up period was 14% for Cymbalta and 42% for placebo.
Incidenca relapsa v 6-mesečnem obdobju dvojno slepega sledenja je bila 14 % pri prejemnikih zdravila Cymbalta oziroma 42 % pri prejemnikih placeba.
The incidence of relapse during the 6- months double-blind follow-up period was 14% for Xeristar and 42% for placebo.
Incidenca relapsa v 6-mesečnem obdobju dvojno slepega sledenja je bila 14 % pri prejemnikih zdravila Xeristar oziroma 42 % pri prejemnikih placeba.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Thymanax and placebo, respectively.
Pojavnost relapsov med 6-mesečnim dvojno slepim spremljanjem je znašala 22 % za zdravilo Thymanax oziroma 47 % za placebo.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Valdoxan and placebo, respectively.
Pojavnost relapsov med 6-mesečnim dvojno slepim spremljanjem je znašala 22 % za zdravilo Valdoxan oziroma 47 % za placebo.
The incidence of relapse during the 6-months double-blind follow-up period was 14% for Duloxetine Lilly and 42% for placebo.
Incidenca relapsa v 6-mesečnem obdobju dvojno slepega sledenja je bila 14 % pri prejemnikih zdravila Duloxetine Lilly oziroma 42 % pri prejemnikih placeba.
The incidence of resistance to caspofungin by various clinical isolates of Candida and Aspergillus is rare.
Pojavnost rezistence na kaspofungin pri različnih kliničnih izolatih vrste Candida in Aspergillus je redka.
The incidence of seizure events was low and comparable in patients receiving Plegridy (125 micrograms every 2 weeks) and placebo (<1% in each group).
Incidenca epileptičnih napadov je bila nizka in primerljiva pri bolnikih, ki so prejemali zdravilo Plegridy (125 mikrogramov vsaka 2 tedna) in placebo (< 1 % v vsaki skupini).
The incidence of serious adverse events was higher in the older people patients compared to younger patients.
Incidenca resnih neželenih učinkov je bila pri starejših bolnikih večja kot pri mlajših.
The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA treated patients and 2.4% in control patients.
Incidenca resnih neželenih učinkov, ki so se pojavili v vseh kliničnih študijah, je bila 2,2 % pri bolnikih, zdravljenih z zdravilom JETREA, in 2,4 % pri kontrolnih bolnikih.
The incidence of serious events related to depression and suicidal ideation were similar and low (<1%) in both Plegridy 125 micrograms every 2 weeks and placebo-treated patients.
Incidenca resnih neželenih dogodkov, povezanih z depresijo in samomorilnimi mislimi, je bila podobna in nizka (< 1 %) za bolnike, zdravljene z zdravilom Plegridy 125 mikrogramov vsaka 2 tedna, in za bolnike, ki so prejemali placebo.
The incidence of serious infections in RA studies conducted at the recommended dose (100 mg/day) was 1.8% in Kineret treated patients and 0.7% in placebo-treated patients.
Incidenca resnih okužb v študijah RA, opravljenih s priporočenim odmerkom (100 mg/dan) je bila 1,8 % pri bolnikih zdravljenih z zdravilom Kineret in 0,7 % pri bolnikih, ki so dobivali placebo.
The incidence of serious infections was 0.03 per patient year in Trudexa treated patients and 0.03 per patient year in placebo and active control−treated patients.
Incidenca resnih okužb je bila 0,03 na bolnik-leto med bolniki, ki so dobivali Trudexo, in 0,03 na bolnik-leto med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per patient year in placebo and active control − treated patients.
Incidenca resnih okužb je bila 0,04 na bolnikov-let med bolniki, ki so dobivali zdraviloHumira, in 0,03 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
The incidence of severe cases was similar for clopidogrel and ASA.
Incidenca hujših primerov krvavitev je bila podobna pri klopidogrelu 1,4- odstotna, pri ASA pa1,6-odstotna.
The incidence of severe haemorrhagic events (Grade ≥ 3) was 2.1% in cabozantinib-treated RCC patients (7/331).
Incidenca dogodkov hude krvavitve (≥ 3. stopnje) je bila 2,1 % pri bolnikih s KLC, zdravljenih s kabozantinibom (7/331).
The incidence of severe haemorrhagic events (Grade ≥3) occurred in 2.2% of the overall trastuzumab emtansine treated patients and 1.8% of Asian trastuzumab emtansine treated patients.
Incidenca hudih krvavitev (≥ 3. stopnje) med zdravljenjem s trastuzumabom emtanzinom je bila 2,2 % med vsemi bolniki in 1,8 % med azijskimi bolniki.
The incidence of severe nausea and vomiting was 4%.
Pojavnost hude slabosti in bruhanja je bila 4 %.
The incidence of side effects after topical ophthalmic administration is lower than when medicines are, for example, taken by mouth or injected.
Pogostnost neželenih učinkov po topikalni očesni uporabi je manjša, kot kadar zdravilo npr. zaužijemo ali injiciramo.
The incidence of skin laceration (29.1%) was higher for subjects treated with two concurrent injections of Xiapex in historically-controlled clinical study AUX-CC-867 compared with subjects treated with up to three single injections in the Phase 3 placebo-controlled pivotal studies in Dupuytren’s contracture (CORD I and CORD II) (8.8%).
Incidenca raztrganja kože (29,1 %) je bila v klinični študiji AUX-CC-867, nadzorovani z obstoječimi podatki, večja za osebe, zdravljene z dvema sočasnima injekcijama zdravila Xiapex, v primerjavi z osebami, zdravljenimi z do tremi enkratnimi injekcijami v ključnih študijah 3. faze za Dupuytrenovo kontrakturo, nadzorovanih s placebom (CORD I in CORD II) (8,8 %).
The incidence of some adverse reactions was higher in paediatric patients than in adult patients (see section 4.8).
Incidenca nekaterih neželenih učinkov je bila pri otrocih večja kot pri odraslih (glejte poglavje 4.8).
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson’s patients.
Incidenca nekaterih dopaminergičnih neželenih učinkov, kot so halucinacije, diskinezija in perferni edem, je na splošno večja pri uporabi v kombinaciji z L-dopo pri bolnikih s Parkinsonovo boleznijo.
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson’s patients.
Incidenca nekaterih dopaminergičnih neželenih učinkov, kot so halucinacije, diskinezija in periferni edem, je na splošno večja pri uporabi v kombinaciji z L-dopo pri bolnikih s Parkinsonovo boleznijo.
The incidence of somnolence is increased at doses higher than 1.5 mg/day (see section 4.2).
Zaspanost je pogostejša pri dnevnih odmerkih, ki so večji od 1,5 mg (glejte poglavje 4.2).
The incidence of symptomatic cardiac dysfunction was 1.7% in the Herceptin arm.
Pogostnost simptomatske motnje v delovanju srca je bila v skupini, ki je prejemala zdravilo Herceptin, 1,7 %.
The incidence of symptomatic LVD (congestive heart failure) was 1.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC (this excludes a patient who experienced symptomatic LVD during FEC treatment prior to receiving Perjeta plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta in combination with TCH.
Incidenca simptomatskega LVD (kongestivno srčno popuščanje) je bila 1,3 % v skupini bolnikov, ki so po zdravljenju s FEC prejeli zdravilo Perjeta, trastuzumabo in docetaksel (izključen je bolnik, pri katerem se je simptomatska LVD pojavila med zdravljenjem s FEC pred prejemom zdravila Perjeta, trastuzumaba in docetaksela) ter tudi 1,3 % v skupini, zdravljeni z zdravilom Perjeta v kombinaciji s shemo TCH.
The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
Incidenca sistemskih neželenih učinkov po topikalni očesni uporabi zdravila je manjša kot pri njegovi sistemski uporabi.
The incidence of systemic adverse reactions after topical ophthalmic administration is lower than for systemic administration.
Incidenca sistemskih neželenih učinkov po topikalni očesni uporabi zdravila je manjša kot pri njegovi sistemski uporabi.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Incidenca naslednjih neţelenih učinkov (vse stopnje) – letargije, stomatitisa in nevtropenične okuţbe – je bila pri bolnikih, starih 65 let ali več, za ≥ 10 % večja kot pri mlajših bolnikih.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Incidenca naslednjih neželenih učinkov (vse stopnje) - letargije, stomatitisa in nevtropenične okužbe - je bila pri bolnikih, starih 65 let ali več, > 10 % večja kot pri mlajših bolnikih.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Incidenca naslednjih neželenih učinkov (vse stopnje) – letargije, stomatitisa in nevtropenične okužbe – je bila pri bolnikih, starih 65 let ali več, za ≥ 10 % večja kot pri mlajših bolnikih.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Incidenca naslednjih neželenih učinkov (vse stopnje) – letargije, stomatitisa in nevtropenične okužbe – je bila pri bolnikih, starih 65 let ali več,  10 % večja kot pri mlajših bolnikih.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates  10% higher in patients who were 65 years of age or older compared to younger patients.
Incidenca naslednjih neželenih učinkov (vse stopnje) – letargije, stomatitisa in nevtropenične okužbe – je bila pri bolnikih, starih 65 let ali več,  10 % večja kot pri mlajših bolnikih.
The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a hazard ratio 0.493 (95% CI: 0.308 - 0.789).
Incidenca sekundarnega varnostnega izida (velike krvavitve) je bila nižja v skupini, ki je prejemala rivaroksaban (1,1 % (26/2412)) kot v skupini, ki je prejemala enoksaparin/antagoniste vitamina K (2,2 % (52/2405)) z razmerjem tveganja 0,493 (95 % IZ: 0,308 - 0,789).
The incidence of these additional RAS mutations (KRAS exons 3, 4 and NRAS exons 2, 3, 4) in the wild-type KRAS (exon 2) population was approximately 10%.
Incidenca teh dodatnih mutacij RAS (KRAS eksonov 3, 4 ter NRAS eksonov 2, 3, 4) v populaciji z divjim tipom KRAS (ekson 2) je bila približno 10 %.
The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
Pogostnost pojava teh neželenih reakcij je odvisna od odmerka zdravila, bolnikove starosti in morda v obratnem sorazmerju z njegovo starostjo ob pojavu pomanjkanja rastnega hormona.
The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
Pogostnost pojava teh neželenih reakcij je odvisna od odmerka zdravila, bolnikove starosti in morda v obratnem sorazmerju z njegovo starostjo ob pojavu pomanjkanja rastnega hormona..
The incidence of these adverse reactions, possibly reflecting meningeal irritation, are headache (24%), nausea (18%), vomiting (17%), pyrexia (12%), neck stiffness (3%), neck pain (4%), back pain (7%), meningism (<1%), convulsions (6%), hydrocephalus (2%), and CSF pleocytosis with or without altered state of consciousness (1%).
Ti neželeni učinki, ki so morda odraz draženja možganskih ovojnic, vključujejo glavobol (24%), slabost (18%), bruhanje (17%), povišano telesno temperaturo (12%), togost vratu (3%), bolečine v vratu ( 4%), bolečine v hrbtu (7%), meningizem (<1%), konvulzije (6%), hidrocefalijo (2%) ter pleocitozo likvorja z motnjo zavesti ali brez nje (1%).